Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral Smarca2 Selective Inhibitor Fhd-909 in a Phase 1 Trial for Smarca4 Mutated Solid Tumors
foghorn therapeutics宣佈,第一名患者接受了首個口服Smarca2選擇性抑制劑fhd-909,用於Smarca4突變實體腫瘤的1期臨床試驗
Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral Smarca2 Selective Inhibitor Fhd-909 in a Phase 1 Trial for Smarca4 Mutated Solid Tumors
foghorn therapeutics宣佈,第一名患者接受了首個口服Smarca2選擇性抑制劑fhd-909,用於Smarca4突變實體腫瘤的1期臨床試驗
譯文內容由第三人軟體翻譯。